推荐产品
等級
pharmaceutical primary standard
API 家族
abiraterone
製造商/商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChI
1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChI 密鑰
UVIQSJCZCSLXRZ-UBUQANBQSA-N
基因資訊
human ... CYP17A1(1586)
正在寻找类似产品? 访问 产品对比指南
一般說明
Abiraterone acetate is a pro-drug of abiraterone and a potent inhibitor of the enzyme CYP17, required for androgen biosynthesis in the adrenal glands, testes and prostate tissue.
應用
Abiraterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Abiraterone Acetate Tablets
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險聲明
危險分類
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
標靶器官
Endocrine system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Danila.CD, et al.
Journal of Clinical Oncology, 28(9), 1496-1501 (2010)
Ryan.JC, et al.
Journal of Clinical Oncology, 28(9), 1481-1488 (2010)
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Ryan.JC, et al.
Clinical Cancer Research, 14(7), 4854-4861 (2011)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门